Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants ofchemokine mRNA expression during infection with Trypanosoma cruzi
A. Talvani et al., Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants ofchemokine mRNA expression during infection with Trypanosoma cruzi, MICROBES IN, 2(8), 2000, pp. 851-866
We investigated the kinetics of parasite replication, leukocyte migration,
and cytokine/chemokine mRNA expression in the heart tissue from animals inf
ected with the Colombiana strain of Trypanosoma cruzi. Cardiac tissue paras
itism was noticeable at 15 days, peaked around 30 days and was dramatically
reduced at 120 days postinfection (p.i.), Kinetic studies showed that the
inflammatory infiltrate was dominated by the presence of alpha beta T CD3() CD4(+) CD8(-), alpha beta T CD3(+) CD4(-)CD8(+) lymphocytes and macrophag
es. The mRNA expression of the monokines IL-1 beta and IL-12(p40) was eleva
ted at 15 days p,i. and controlled at later time points. In contrast, TNF-a
lpha mRNA was expressed throughout the infection. Interestingly, we found t
hat at 15 and 30 days p.i. cytokine expression was dominated by the presenc
e of IFN-gamma mRNA, whereas at 60 days or later time points the balance of
type 1 and type 2 cytokines was switched in favor of IL-4 and IL-10 mRNAs,
The chemokine mRNAs encoding JE, MIP-l alpha, MIP-1 beta, KC, and MIP-2 we
re all mainly expressed at 15 and/or 30 days p,i. and diminished thereafter
. In contrast, the expression of RANTES, MIG and IP-10 mRNAs was augmented
at 15 days p.i. and persisted at high levels up to 120 days p,i. Taken toge
ther, our results indicate that regulation of IFN-gamma and chemokine expre
ssion, associated with decreased tissue parasitism, may be largely responsi
ble for the control of inflammation and immunopathology observed in the car
diac tissue of animals infected with ir: cruzi. (C) 2000 Editions scientifi
ques et medicales Elsevier SAS.